Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Best Buy Co Inc (BBY) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Best Buy Co IncTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Best Buy Co Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Best Buy Co Inc trades at $82.59 (market cap $17.37B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Best Buy Co Inc is the larger of the two by market cap, and Best Buy Co Inc pays a 4.66% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BBYBIO
Market Cap
$17.37B$9.39B
Sector
Consumer CyclicalHealth
52-Week High
$90.17$356.25
52-Week Low
$55.52$241.71
Enterprise Value
$19.75B$9.14B
Dividend Yield
4.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Best Buy Co Inc

Best Buy (BBY) trades at $82.00, up 2.47% today, with a bearish technical signal and mixed sentiment. Recent earnings beats and a forward P/E of 15.19 suggest reasonable valuation, but revenue has declined from $51.8B in 2022 to $41.5B in 2025. The company is testing smaller store formats and appointed a new CFO in August 2026, aiming to stabilize operations amid leadership changes.

Outlook is cautious; analyst consensus is a Hold with a $81.69 price target. Opportunities include cost control and dividend yield, but risks involve persistent revenue pressure, competitive threats, and execution risks from management turnover. Net cash flow turned positive in 2025, yet margin compression remains a concern for sustained growth.

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO